Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
Presentations from ISPOR and HTAi 2018
12 July 2018
OHE staff recently attended ISPOR and HTAi international conferences. In this blog post, we share a selection of our presentations.
Invitation to OHE’s Annual Lecture 2018: Is There an Economic Case for Investing in the NHS? Really?
11 July 2018
Join OHE for an evening lecture with Professor Peter Smith on Tuesday 4 September 2018 at the Royal College of Physicians, London.
What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?
9 July 2018
The OHE has published a report exploring the impact on payers, patients and innovators of differential prices for different uses of pharmaceuticals.
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
3 July 2018
Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such asimmunotherapies. In the economic modelling of such treatments, the question arises of which utilities should be assigned to patients who show a long-term, durable response.
New Publications: Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
18 April 2018
Just published are two new reports that explore the use of real world evidence for coverage and formulary decisions. The publications represent 1) the background paper…
Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?
4 April 2018
A recently published editorial by OHE’s David Mott considers whether quantitative patient preference data has a role to play in HTA decision making.
Value Frameworks: Value in Health Special Issue
29 March 2018
A recent issue of Value in Health contains the ISPOR Special Task Force Report on US Value Assessment Frameworks. In this blog post, we summarise the…
Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?
22 March 2018
A new OHE report discusses NICE’s introduction of a cost-effectiveness threshold to appraise ultra-orphan drugs.
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
1 December 2018
This report provides a detailed summary of a panel discussion held at the HTAi 2017 annual meeting in Rome on the current approaches to MIP in…